Sitemap - 2026 - The Billion Dollar Blindspot
When Women's Health Meets Institutional Capital
Why Women's Health Is the First Test of Precision Health
The Work Behind This Newsletter and What Comes Next.
When Care Becomes Leverage: Who Owns Women’s Health Infrastructure?
Being Diagnosed Isn't the Same as Being Studied
Was ADHD Built for Boys? Why Thousands of Women Are Being Diagnosed Decades Later
Women Now Spend a Third of Their Lives After Menopause. Medicine Hasn't Caught Up.
Why Women’s Health Became a Billion-Dollar Blind Spot in Capital Markets
The Billion Dollar Blind Spot Began in a Doctor’s Office
The Future of Medicine Is Being Built on Incomplete Biology
What Menopause Is Actually Doing to the Heart
The Menopause Information Crisis
The Operation That Shouldn't Still Be Happening
The Great Wealth Transfer and Women's Health: Why These Are the Same Story
Organon Is Telling You Exactly What It Is and the Exit Math for Women's Health Has Changed
Building FemTech Infrastructure in Asia
The Menopause Drug Market Just Split in Two and the Capital Opportunity Is Bigger Than Either Drug
When AI Gets It Right (and Wrong) on Women’s Health
📕I have news and it's been a long time coming!
The System That Ate Healthcare
Before Venture Shows Up | How Catalytic Capital Creates Women’s Health Markets
Why It Takes Years to Build in Women’s Health
Why “Low Libido” Isn’t One Problem
Menopause is not shrinking your brain although the headlines want you to believe it is
Why Women’s Heart Disease Is Still Misdiagnosed
Why Fasting Feels Different in Midlife Women
The Myth of Safety: Why Cash Is Not Neutral After 40
How Hormones Change Women’s Hearts and Why Cardiology Wasn’t Built to See It